[go: up one dir, main page]

WO2010028130A3 - Antidepressant compounds - Google Patents

Antidepressant compounds Download PDF

Info

Publication number
WO2010028130A3
WO2010028130A3 PCT/US2009/055865 US2009055865W WO2010028130A3 WO 2010028130 A3 WO2010028130 A3 WO 2010028130A3 US 2009055865 W US2009055865 W US 2009055865W WO 2010028130 A3 WO2010028130 A3 WO 2010028130A3
Authority
WO
WIPO (PCT)
Prior art keywords
antidepressant compounds
compounds
antidepressant
desvenlafaxine
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/055865
Other languages
French (fr)
Other versions
WO2010028130A2 (en
Inventor
Roger Tung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of WO2010028130A2 publication Critical patent/WO2010028130A2/en
Publication of WO2010028130A3 publication Critical patent/WO2010028130A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to deuterated forms of desvenlafaxine and the use of such compounds in pharmaceutical composition and for treatment of psychological disorders.
PCT/US2009/055865 2008-09-03 2009-09-03 Antidepressant compounds Ceased WO2010028130A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9404508P 2008-09-03 2008-09-03
US61/094,045 2008-09-03

Publications (2)

Publication Number Publication Date
WO2010028130A2 WO2010028130A2 (en) 2010-03-11
WO2010028130A3 true WO2010028130A3 (en) 2010-06-10

Family

ID=41797846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/055865 Ceased WO2010028130A2 (en) 2008-09-03 2009-09-03 Antidepressant compounds

Country Status (1)

Country Link
WO (1) WO2010028130A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2998288B1 (en) 2005-12-01 2022-08-24 ACADIA Pharmaceuticals Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
DK2125698T3 (en) 2007-03-15 2016-11-07 Auspex Pharmaceuticals Inc Deuterated d9-VENLAFAXINE
CN104326923B (en) * 2014-09-05 2016-02-10 南京华威医药科技开发有限公司 A kind of synthetic method of succsinic acid desmethylvenlafaxine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030537A1 (en) * 2005-09-07 2007-03-15 Wyeth Topical formulations containing o-desmethyl venlafaxine (odv) or its salts
US20070293480A1 (en) * 2006-06-16 2007-12-20 Theracos, Inc. Treating psychological conditions using muscarinic receptor m1 antagonists
WO2008140859A1 (en) * 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
US20090076162A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched desvenlafaxine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030537A1 (en) * 2005-09-07 2007-03-15 Wyeth Topical formulations containing o-desmethyl venlafaxine (odv) or its salts
US20070293480A1 (en) * 2006-06-16 2007-12-20 Theracos, Inc. Treating psychological conditions using muscarinic receptor m1 antagonists
WO2008140859A1 (en) * 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
US20090076162A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched desvenlafaxine

Also Published As

Publication number Publication date
WO2010028130A2 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
EA201101190A1 (en) A PHARMACEUTICAL COMPOSITION INCLUDING LINAGLIPTIN AND OPTIONAL SGLT2 INHIBITOR AND ITS APPLICATION
WO2012075383A3 (en) Bromodomain inhibitors and uses thereof
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2011009539A (en) Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof.
CL2008000531A1 (en) COMPOUNDS DERIVED FROM HETEROCICLES, INHIBITORS OF ASPARTILPROTEASA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF CARDIOVASCULAR, COGNITIVE AND NEURODEGENERATIVE DISEASES SUCH AS THE DISEASE
IL225198A (en) Aminotetrahydropyran compounds, pharmaceutical compositions comprising the same and the use thereof for the treatment of diabetes
WO2012174487A3 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
UY32456A (en) FAMOUS COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
CL2008000981A1 (en) COMPOUNDS DERIVED FROM IMIDAZOLIDIN-CARBOXAMIDA; PHARMACEUTICAL COMPOSITION; PROCEDURE OF PRODUCTION OF THE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROTIC DISORDERS, OF FATTY ACIDS METABOLISM AND IN WHICH
EA201170356A1 (en) POLYMORPHIC AND AMORPHOUS FORMS OF LACOSAMIDE AND AMORPHOUS COMPOSITIONS
EE201300007A (en) Combined pharmaceutical composition for the treatment of diabetes and metabolic disorders
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
ZA201009072B (en) Pharmaceutical composition for the treatment of premature ejaculation
CL2008000982A1 (en) COMPOUNDS DERIVED FROM 5-OXO-ISOXAZOL-CARBOXAMIDA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PROCEDURE OF PRODUCTION OF THE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROTIC DISORDERS, OF METABOLISM OF
CL2012000097A1 (en) Compounds derived from 3-phenoxymethylpyrrolidine, serotonin-norepinephrine reuptake inhibitors; preparation procedure; intermediate compounds; pharmaceutical composition comprising it; and its use in the treatment of pain disorders, depression, among others.
IL213177A0 (en) Crystal forms, methods of preparation, pharmaceutical compositions and uses of nicousamide
WO2010028130A3 (en) Antidepressant compounds
WO2008130319A3 (en) Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain
WO2008094054A3 (en) 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
GB201312583D0 (en) Combination and composition for treating obesity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09812206

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09812206

Country of ref document: EP

Kind code of ref document: A2